Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. - Wikidata - wikimedia - TriplyDB

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.

http://www.wikidata.org/entity/Q34049626

about

Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review.The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.Immune System and Schizophrenia Cytokines and glucocorticoid receptor signaling. Relevance to major depression Celecoxib reduces glucocorticoids in vitro and in a mouse model with adrenocortical hyperplasia.Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders.Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression.The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders--relation to drug treatment.Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions.Bipolar Spectrum Disorders in Male Youth: The Interplay between Symptom Severity, Inflammation, Steroid Secretion, and Body Composition.Therapeutic strategies for treatment of inflammation-related depression.Different susceptibility of prefrontal cortex and hippocampus to oxidative stress following chronic social isolation stress.Hippocampal upregulation of the cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression).Synthesis and evaluation of 2-(2-arylmorpholino)ethyl esters of ibuprofen hydrochlorides as COX-2 and serotonin reuptake inhibitors.

P2860

Q28220405-84364957-F7C4-41FB-B359-FB1D40A846BE Q33587452-F88F13CC-2CB4-42DE-9ADA-C8C934BE174E Q34384181-00369A6D-4BD9-461C-B696-7EBC10E42F47 Q34496400-D9A2B1EF-7C8E-4083-8921-C78889AD195B Q34625031-4FB7F02B-257F-4CE5-8976-B0E163B19BC0 Q36101717-03AFBF8F-7A0E-4474-9165-F0D4F764D8AC Q36319490-74A789DC-AF6D-46F8-9887-22E88ABED3AE Q36532151-BD8552B7-59A1-4924-A1BE-8D35EBEEE5FB Q36637116-3589BCA1-F4DD-496A-9957-D330972F6E6A Q37624657-87A260FC-86C4-4375-BF71-5886174E0788 Q38983429-2C771B47-2858-4B7C-97F4-70286A12A971 Q47101588-E1450ACA-A0BA-4913-8915-67FB4E342666 Q47785792-E7874378-0A57-4E57-8322-EB5D3E58ACC0 Q48326454-CADCD79D-E0F1-4DF6-81BE-50C250DEDE1C Q48602700-E111B6BF-5F26-4697-A340-D714DC7B39E3 Q53670033-EAB8869C-C892-4901-AAB4-324ECDB5B5EC

P2860

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.

http://www.wikidata.org/entity/Q34049626

description

2005 nî lūn-bûn

@nan

2005 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.

@ast

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.

@en

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.

@nl

type

label

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.

@ast

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.

@en

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.

@nl

prefLabel

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.

@ast

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.

@en

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.

@nl

P1433

Q34049626-0ECFE302-0DC1-42B2-9DA5-252B7CBDC280

P1476

Q34049626-AC994ED1-82AD-44C6-81E5-59427017AD0C

P2093

Q34049626-3741991B-7984-4F0C-BFFD-8C6FC6E2A5F1

Q34049626-55E564C2-4104-40A4-B209-27268A58983C

Q34049626-6E09CC89-873C-4E3E-A0A7-A85CCB200ECC

Q34049626-99083D13-EEF8-4235-8ED6-FF44A0640E1E

Q34049626-E9CB296F-CA6E-48D6-83E9-C59B6720A62D

P2860

Q34049626-009292F1-5D4F-4D96-BD81-EF01EEC96CF6

Q34049626-0D6B97AE-BB00-44D7-A006-4F92751E12FB

Q34049626-407EF313-2918-4632-8148-167E1D400C0C

Q34049626-4E18B5FA-C0C0-4E59-9D11-E99BA79A3FE8

Q34049626-6B9F4987-DAA1-4858-8314-53E2BD8BD857

Q34049626-78B5EC21-A5FC-444C-9976-593D3077096F

Q34049626-7D9F3397-40EC-4F20-A6F0-24CC74B84FCE

Q34049626-A5C224BF-3C19-4323-A2EF-D84ED0D3CAAC

Q34049626-AA00972B-B91E-4D72-9DEB-7541B24EB8E2

Q34049626-C81DB544-D2B5-4BFD-BB86-6D51FFA1A4D7

P2888

Q34049626-880CE701-EB49-4E37-B2E3-EF9D5D1BDE38

P304

Q34049626-1AC51FCA-F728-477B-9C6C-8829F0BAB820

P31

Q34049626-E4B5B603-CDFD-4EB1-AD0A-898DE89DA0C3

P356

Q34049626-A0C23DE1-365B-4108-93C1-91CAFC8FE788

P407

Q34049626-91CAA47D-C874-4B73-AFB4-7F160C4BEF0C

P433

Q34049626-FE5ED9F2-C554-4287-9D61-DDAB14B17053

P478

Q34049626-B00144E5-7FFC-456C-A096-98F1C0D9762F

P577

Q34049626-BDA398C5-AFDB-4A29-9996-2BD87031BE8A

P5875

Q34049626-D52ADDF6-A450-400E-BA6C-7F418FDBA4FD

P698

Q34049626-475C02B3-2BA2-4594-904B-20F77B6FC20F

P932

Q34049626-0C2D8C04-A55B-4AF7-92FD-24EF06CCAA45

P356

P1433

Molecular Psychiatry

P1476

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.

@en

P2093

A H Miller

http://www.w3.org/2001/XMLSchema#string

F Hu

http://www.w3.org/2001/XMLSchema#string

H Wu

http://www.w3.org/2001/XMLSchema#string

T W W Pace

http://www.w3.org/2001/XMLSchema#string

X Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Nonsteroidal anti-inflammatory drugs suppress T-cell activation by inhibiting p38 MAPK induction

Inflammatory blockade restores adult hippocampal neurogenesis

The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection

Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment.

When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders.

Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase.

Interleukin 1alpha (IL-1alpha) induced activation of p38 mitogen-activated protein kinase inhibits glucocorticoid receptor function.

The steroid receptor antagonists RU40555 and RU486 activate glucocorticoid receptor translocation and are not excreted by the steroid hormones transporter in L929 cells.

Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine.

A role for COX-2 and p38 mitogen activated protein kinase in long-term depression in the rat dentate gyrus in vitro.

P2888

P304

426-428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.MP.4001644

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8032761

http://www.w3.org/2001/XMLSchema#string

P698

15700047

http://www.w3.org/2001/XMLSchema#string

P932

1237050

http://www.w3.org/2001/XMLSchema#string